Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Analysts are anticipating strong results driven by the strong demand of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential challenges from